Actinium Pharmaceuticals, Inc.’s lead radioligand candidate, Iomab-B, has hit the mark in a pivotal study in pre-transplant relapsed or refractory acute myeloid leukemia patients (r/r AML), marking a key milestone in its journey to disrupt bone marrow transplant (BMT) care.
The Phase III SIERRA trial studied Iomab-B as a conditioning regimen versus standard of care in 153 r/r AML patients...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)